Journal issues > Issue 1, February 2021 > Highlights in chronic lymphocytic leukaemia

Highlights in chronic lymphocytic leukaemia

SUMMARY

Our recent BHS guidelines for the management of small lymphocytic lymphoma (SLL) and chronic lymphocytic leukaemia (CLL) made by the BHS lymphoproliferative disease committee are not challenged after ASH 2020. One educational session discussed “chemotherapy-free frontline therapy for CLL” and “standard approaches for the relapsed/refractory (R/R) CLL after chemoimmunotherapy (CIT) or novel agents”. Managing toxicities of targeted therapies (BTKi, Pi3Ki, and venetoclax) was the topic of another educational session. Andrew Roberts highlighted the importance of bcl-2 inhibition in CLL and other hematological malignancies in the Ham-Wasserman session.

(BELG J HEMATOL 2021;12(1):25-8)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top